
1. Int J Infect Dis. 2021 Oct 29;114:58-61. doi: 10.1016/j.ijid.2021.10.048. [Epub
ahead of print]

Post-acute COVID-19 syndrome after reinfection and vaccine breakthrough by the
SARS-CoV-2 Gamma variant in Brazil.

Penetra SLS(1), da Silva MFB(1), Resende P(2), Pina-Costa A(3), Santos HFP(1),
Guaraldo L(1), Calvet GA(1), Ogrzewalska M(2), Arantes I(2), Zukeram K(2), de
Araújo MF(2), Lima ABM(2), Lopes RS(2), Lira-Silva LR(1), Moraes IV(1), Wakimoto 
MD(1), Fuller TL(4), Gabaglia CR(5), Espíndola OM(1), Bonaldo MC(6),
Daniel-Ribeiro CT(7), Whitworth J(8), Smith C(8), Nielsen-Saines K(9),
Pauvolid-Correa A(10), Siqueira MM(2), Brasil P(11).

Author information: 
(1)Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz
Foundation (Fiocruz) Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ,
21040-3608, Brazil.
(2)Laboratory of Respiratory Viruses and Measles National Influenza Centre
(GISRS-WHO) - Americas Regional Reference Lab for Measles and Rubella - Reference
Laboratory for COVID-19 (WHO), Oswaldo Cruz Institute, (IOC), Fiocruz. Avenida
Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
(3)Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz
Foundation (Fiocruz) Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ,
21040-3608, Brazil; Serra dos Órgãos Education Foundation, Avenida Alberto
Tôrres, 111 - Alto, Teresópolis, RJ, 25964-004, Brazil.
(4)Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz
Foundation (Fiocruz) Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ,
21040-3608, Brazil; University of California, Los Angeles (UCLA), Box 951752,
10833 Le Conte Avenue 22-442 MDCC, Los Angeles, CA, 90095-1752, USA.
(5)Biomedical Research Institute of Southern California (BRISC), 4263 Oceanside
Blvd#106-159, Oceanside, CA, 92056, USA.
(6)Laboratory of Molecular Biology, Oswaldo Cruz Institute, Fiocruz, Avenida
Brasil 4365 - Manguinhos, Rio de Janeiro, RJ 21040-3608, Brazil.
(7)Department of Immunology, Oswaldo Cruz Institute, Fiocruz, Avenida Brasil 4365
- Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil.
(8)Department of Clinical Research, London School of Hygiene and Tropical
Medicine, Keppel St, London, WC1E 7HT, United Kingdom.
(9)University of California, Los Angeles (UCLA), Box 951752, 10833 Le Conte
Avenue 22-442 MDCC, Los Angeles, CA, 90095-1752, USA.
(10)Laboratory of Respiratory Viruses and Measles National Influenza Centre
(GISRS-WHO) - Americas Regional Reference Lab for Measles and Rubella - Reference
Laboratory for COVID-19 (WHO), Oswaldo Cruz Institute, (IOC), Fiocruz. Avenida
Brasil 4365 - Manguinhos, Rio de Janeiro, RJ, 21040-3608, Brazil; Texas A&M
University, 400 Bizzell St, College Station, TX, 778434, USA.
(11)Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz
Foundation (Fiocruz) Avenida Brasil 4365 - Manguinhos, Rio de Janeiro, RJ,
21040-3608, Brazil. Electronic address: patricia.brasil@ini.fiocruz.br.

We describe a case of prolonged COVID-19 caused by the SARS-CoV-2 Gamma variant
in a fully vaccinated healthcare worker, 387 days after an infection caused by
lineage B.1.1.33. Infections were confirmed by whole-genome sequencing and
corroborated by the detection of neutralizing antibodies in convalescent serum
samples. Considering the permanent exposure of this healthcare worker to
SARS-CoV-2, the waning immunity after the first infection, the low efficacy of
the inactivated vaccine at preventing COVID-19, the immune escape of the Gamma
variant (VOC), and the burden of post-COVID syndrome, this individual would have 
benefited from an additional dose of a heterologous vaccine.

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

DOI: 10.1016/j.ijid.2021.10.048 
PMCID: PMC8553653
PMID: 34757006 

